Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T38562 |
AKN-028
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
AKN-028 是酪氨酸激酶 FLT3的抑制剂,可剂量依赖性的诱导 FLT3的自磷酸化。 | |||
T79745 | IDH2R140Q-IN-2 | Dehydrogenase | Metabolism |
IDH2R140Q-IN-2 是一种具有口服活性和高效性的 IDH2R140Q 抑制剂,IC50为29 nM。IDH2R140Q-IN-2 具有潜在的抗肿瘤活性,能减少携带IDH2R140Q突变的TF-1细胞系中D2HG的生成(IC50为10 nM),抑制肿瘤组织中D2HG的水平。IDH2R140Q-IN-2适用于研究急性髓系白血病(AML)。 | |||
T31221L |
dBRD9 HCl
dBRD9 HCl(2170679-45-3 Free base) |
Epigenetic Reader Domain | Chromatin/Epigenetic |
dBRD9 HCl 是一种PROTAC,包含cereblon E3连接酶配体与BRD9抑制剂BI 7273。dBRD9 HCl 是有效和选择性的BRD9降解剂,在MOLM-13细胞中IC50的为56.6nM。dBRD9 HCl 在浓度高达5μM 时不会降解BRD4或BRD7。dBRD9 HCl 在人AML 细胞系中显示出抗增殖作用。 | |||
T28999 |
TPC-144
TPC144,TPC 144 |
||
TPC-144 is a potent and selective LSD1 inhibitor with a reversible inhibition mechanism. TPC-144 has antitumor activity in several human AML and SCLC cell lines and xenograft models. | |||
T71395 |
Rohinitib
|
||
Rohinitib 是一种有效的以及特异性的eIF4A 抑制剂。Rohinitib 诱导急性髓系白血病 (AML) 细胞系的凋亡,并减轻在 AML 异种移植模型小鼠的白血病负担。Rohinitib 可用于 AML 的研究。 | |||
T10464L |
Atuveciclib Racemate
BAY-1143572 Racemate,阿维西利 |
CDK | Cell Cycle/Checkpoint |
Atuveciclib Racemate (BAY-1143572 Racemate) 是 Atuveciclib 的外消旋混合物。 Atuveciclib 是口服有效的 P-TEFb/CDK9高选择性抑制剂,CDK9/CycT1的 IC50为13 nM。 | |||
T35531 |
FD223
|
||
FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC50=1 nM) and good selectivity over other isoforms (IC50s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML[1]. | |||
T74919 | QA-68 | ||
QA-68 (QA-68-ZU81) 为一种高效BRD9降解剂。该化合物抑制细胞周期进展与细胞集落生成,对急性髓系白血病(AML)细胞系展现出抗增殖能力。 | |||
T36681 |
Sorafenib N-oxide
|
||
Sorafenib N-oxide is an active metabolite of sorafenib , an inhibitor of Raf-1, B-RAF, and receptor tyrosine kinases. Sorafenib N-oxide inhibits FLT3 that contains the internal tandem duplication mutation (FLT3-ITD; Kd = 70 nM) and inhibits proliferation of MV4-11 acute myeloid leukemia (AML) cells expressing FLT3-ITD (IC50 = 25.8 nM). It is selective for AML cell lines containing FLT3-ITD over lines containing wild-type FLT3 (IC50s = 3.9-13.3 μM). Sorafenib N-oxide is also a linear-mixed inhibi... | |||
T62099 |
LSD1-IN-13
|
||
LSD1-IN-13 (compound 7e) 是一种口服具有活力的 LSD1 抑制剂 (IC50: 24.43 nM),也能够激活 CD86 表达 (EC50: 470 nM)。LSD1-IN-13 可以诱导 AML (急性髓系白血病) 细胞系分化。 | |||
T62679 |
LSD1-IN-13 hydrochloride
|
||
LSD1-IN-13 hydrochloride (compound 7e) 是一种口服具有活力的 LSD1 抑制剂 (IC50: 24.43 nM)。LSD1-IN-13 hydrochloride 能够激活 CD86 表达 (EC50: 470 nM)。LSD1-IN-13 hydrochloride 可以诱导 AML (急性髓系白血病) 细胞系分化。 | |||
T79086 |
MC4171
|
Histone Acetyltransferase | Chromatin/Epigenetic |
MC4171(化合物34)作为KAT8选择性抑制剂,IC50值为8.1 µM。该化合物在多种癌症细胞系中(包括NSCLC和AML)展现中等微摩尔级别抗增殖效果,显示出其研究治疗癌症的可能性。 | |||
T79133 |
UC-764864
|
E1/E2/E3 Enzyme | Ubiquitination |
UC-764864是一种UBE2N抑制剂,能够抑制其酶活性,并对白血病细胞中的UBE2N依赖性信号传导具有细胞毒性作用。此外,UC-764864还能阻断人AML细胞系中先天免疫和炎症相关底物的泛素化。 | |||
T71227 | LGB-321 HCl | ||
LGB-321 is a potent and selective ATP-competitive small molecule inhibitor of PIM kinases (Pan-PIM kinase inhibitor). LGB321 is unique relative to previously described PIM inhibitors, in that it is active in PIM2 dependent cell lines. , a kinase that has proven difficult to inhibit in the cellular context. Consistent with its activity on all three PIM kinases, LGB321 inhibits proliferation of a number of cell lines derived from diverse hematological malignancies, including MM, AML, CML and B-Cel... | |||
T78854 |
WK499
|
||
BCL6-IN-10 (Compound WK499) 是抑制蛋白 BCL6 的化合物。该化合物能干扰 BCL6 与 SMRT 蛋白的结合作用,进而诱导 apoptosis、导致细胞周期阻滞以及 DNA 损伤。针对多种 Acute Myeloid Leukemia (AML) 细胞株,如 OCI-AML3、THP1、MOLM13、HL60, KG1, NB4,BCL6-IN-10 显示出较强的抑制活性,其 IC50s 分别为 0.91、1.63、1.026、7.42、0.87、0.85 μM。 | |||
T68346 | KRN383 | ||
KRN383 also inhibited the proliferation of the ITD-positive cell lines with IC(50) values of < or =2.9 nM. A single oral administration of 80 mg/kg of KRN383 eradicated ITD-positive xenograft tumors in nude mice and prolonged the survival of SCID mice carrying ITD-positive AML cells. The effectiveness of a single oral dose of KRN383 suggests that it has the potential to be used in a wide variety of clinical regimens, including multicycle and combination therapies. | |||
T79322 | Antiproliferative agent-30 | ||
Antiproliferative agent-30 (Compound 8g) 抑制微管蛋白组装且可抑制FLT3及Abl1。该化合物展现出对血管的破坏活性,并对多种癌细胞系表现出强效的抗增殖能力,包括HCT-116、K562及MV-4-11细胞(IC50值分别为0.054 nM、0.008 nM、0.144 nM)。此外,Antiproliferative agent-30 亦对携带FLT3-ITD-TKD突变的AML显示出抗癌效果。 | |||
T79456 |
FD1024
|
Pim | Chromatin/Epigenetic; JAK/STAT signaling |
FD1024是一种PIM抑制剂,对PIM1、PIM2和PIM3的IC50s分别为1.96、38.9及4.17 nM。用于急性髓系白血病研究的FD1024,对AML细胞系显示出显著的抗增殖效果,其对EOL-1、MV-4-11、KG-1和MOLM-16细胞的抑制浓度(IC50s)分别为0.16 μM、0.12 μM、1.05 μM和1.39 μM。此外,FD1024在小鼠模型中也表现出抗肿瘤活性。 | |||
T79596 |
FLT3-IN-20
|
||
FLT3-IN-20(compound 34f)作为一种高效FLT3抑制剂,对FLT3-D835Y和FLT3-ITD具有强效性,IC50值分别仅为1 nM和4 nM。该化合物在携带FLT3-ITD突变的AML细胞系MV4-11和MOLM-13中展现出显著的抗增殖效果,其中IC50值分别为7 nM和9 nM;对于带有FLT3-ITD-D835Y突变的MOLM-13变体,其IC50值为4 nM。FLT3-IN-20主要用于肿瘤治疗研究领域。 |